Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

por Lips, E. H., Mulder, L., de Ronde , J. J., Mandjes, I. A. M., Koolen, B. B., Wessels, L. F. A., Rodenhuis, S., Wesseling, J.
Publicado 2013

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

por Lips, E H, Mulder, L, Oonk, A, van der Kolk, L E, Hogervorst, F B L, Imholz, A L T, Wesseling, J, Rodenhuis, S, Nederlof, P M
Publicado 2013

Enrichment of high-grade tumors in breast cancer gene expression studies

por van Seijen, M., Mooyaart, A. L., Mulder, L., Hoogstraat, M., Drukker, C. A., Loo, C. E., Pouw, B., Sonke, G. S., Wesseling, J., Lips, E. H.
Publicado 2017

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

por Rigter, L S, Loo, C E, Linn, S C, Sonke, G S, van Werkhoven, E, Lips, E H, Warnars, H A, Doll, P K, Bruining, A, Mandjes, I A, Vrancken Peeters, M J, Wesseling, J, Gilhuijs, K G, Rodenhuis, S
Publicado 2013

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

por Liefaard, M. C., van der Voort, A., van Ramshorst, M. S., Sanders, J., Vonk, S., Horlings, H. M., Siesling, S., de Munck, L., van Leeuwen, A. E., Kleijn, M., Mittempergher, L., Kuilman, M. M., Glas, A. M., Wesseling, J., Lips, E. H., Sonke, G. S.
Publicado 2023

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

por Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., Cornelissen, S., Holtkamp, M., Froklage, F. E., de Vries, E. G. E., Schrama, J. G., Wesseling, J., van de Vijver, M. J., van Tinteren, H., de Bruin, M., Hauptmann, M., Rodenhuis, S., Linn, S. C.
Publicado 2011